Want to see JP:4978 full AI Analyst Report?
4978 Stock Chart & Stats
¥143.00
¥3.00(2.91%)
At close: 4:00 PM EST
¥143.00
¥3.00(2.91%)
Day’s Range― - ―
52-Week Range¥116.00 - ¥204.00
Previous CloseN/A
Volume331.50K
Average Volume (3M)488.36K
Market Cap
¥13.46B
Enterprise Value¥6.25B
Total Cash (Recent Filing)¥5.62B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.59
Shares Outstanding106,875,890
10 Day Avg. Volume680,700
30 Day Avg. Volume488,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.88
Price to Sales (P/S)7.46
P/FCF Ratio-34.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)¥3.53B
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of meaningful debt materially limits refinancing and interest-related pressure, while the sizable, relatively stable equity base provides a substantial capital buffer. This gives ReproCELL greater resilience during weak operating periods and preserves flexibility to support research, services, or other business needs.
Resilient Gross Profit BaseMaintaining more than ¥1.0B of gross profit during a difficult revenue year indicates that the company continues to generate meaningful value from its offerings. Although operating costs remain too high, this gross-profit base provides an ongoing platform for improving efficiency and restoring profitability.
Broad Life-science OfferingReproCELL serves biomedical research and drug-discovery customers through both products and contract services, spanning iPSC technologies, cell lines, reagents, and development support. This combination gives the company several ways to participate in research workflows and aligns it with ongoing regenerative-medicine activity.
Bears Say
Persistent Cash BurnPersistent negative free cash flow shows that the business has not consistently funded itself through operations, even when reported net income was positive. Continued cash burn can consume the company’s capital buffer, limit investment capacity, and make a durable recovery dependent on improved cash conversion.
Revenue VolatilityThe reversal from strong growth in 2022 and 2023 to declines in later periods indicates that demand and commercial execution have been uneven. A shrinking revenue base makes fixed operating costs harder to absorb, reduces earnings visibility, and complicates sustained investment in the company’s technology portfolio.
Inconsistent ProfitabilityThe swing from a brief profit in 2025 back to a sizable loss in 2026 demonstrates that profitability is not yet dependable. Deeply negative operating profit suggests the current scale of revenue does not consistently cover operating costs, weakening earnings quality and making future results difficult to predict.
4978 FAQ
What was ReproCELL Inc.’s price range in the past 12 months?
ReproCELL Inc. lowest stock price was ¥116.00 and its highest was ¥204.00 in the past 12 months.
What is ReproCELL Inc.’s market cap?
ReproCELL Inc.’s market cap is ¥13.46B.
When is ReproCELL Inc.’s upcoming earnings report date?
ReproCELL Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 13 days.
How were ReproCELL Inc.’s earnings last quarter?
ReproCELL Inc. released its earnings results on Aug 13, 2026. The company reported -¥1.56 earnings per share for the quarter.
Is ReproCELL Inc. overvalued?
According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued.
Does ReproCELL Inc. pay dividends?
ReproCELL Inc. does not currently pay dividends.
What is ReproCELL Inc.’s EPS estimate?
ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ReproCELL Inc. have?
ReproCELL Inc. has 106,875,890 shares outstanding.
What happened to ReproCELL Inc.’s price movement after its last earnings report?
ReproCELL Inc. reported an EPS of -¥1.56 in its last earnings report. Following the earnings report the stock price went up 0.714%.
Which hedge fund is a major shareholder of ReproCELL Inc.?
Currently, no hedge funds are holding shares in JP:4978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ReproCELL Inc.
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.